Mylan NV (MYL)

43.96
0.81 1.90
NASDAQ : Health Care
Prev Close 43.15
Open 44.65
Day Low/High 43.72 / 45.11
52 Wk Low/High 37.59 / 55.51
Volume 7.43M
Avg Volume 4.66M
Exchange NASDAQ
Shares Outstanding 534.91M
Market Cap 24.40B
EPS 1.80
P/E Ratio 28.51
Div & Yield N.A. (N.A)

Latest News

Stocks Fluctuate as Fed Members Head to Jackson Hole

Stocks Fluctuate as Fed Members Head to Jackson Hole

Stocks fluctuate on Thursday morning as Federal Reserve members head to Jackson Hole, Wyo., for their closely watched summer summit.

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Short-seller Andrew Left says Mallinckrodt has long been gaming the system on its Acthar Gel drug.

More Squawk from Jim Cramer: Mylan (MYL) Should Have More Competition

More Squawk from Jim Cramer: Mylan (MYL) Should Have More Competition

Mylan (MYL) said on Thursday that it would reduce the out-of-pocket cost of its EpiPens, which treat life-threatening allergies.

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. stocks moved slightly lower on Thursday as investors anxiously await remarks from Federal Reserve Chair Janet Yellen on Friday.

Mylan EpiPen Controversy Puts More Biotechs in Danger

Mylan EpiPen Controversy Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

'No One Is More Frustrated Than Me,' Mylan (MYL) CEO Heather Bresch Tells CNBC

'No One Is More Frustrated Than Me,' Mylan (MYL) CEO Heather Bresch Tells CNBC

Mylan (MYL) CEO Heather Bresch told CNBC that the price increase is a result of changing healthcare insurance plans.

Mylan Dispute Puts More Biotechs in Danger

Mylan Dispute Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

Stock Futures Head Lower as Jobless Claims Decline, Durable Goods Increase

Stock Futures Head Lower as Jobless Claims Decline, Durable Goods Increase

Stock futures move lower on Thursday morning as monetary policy officials head to Jackson Hole, Wyo., for their two-day summer summit.

Mallinckrodt's Top Drug Could Go the Way of EpiPen

Mallinckrodt's Top Drug Could Go the Way of EpiPen

The drug that's helping boost the company's stock could become its biggest risk.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

The Fed meets for a monetary policy summit, and investors consider dollar-store earnings and jobless claim numbers.

Morning Movers: SHLD, TIF, DG, DLTR, MYL

Morning Movers: SHLD, TIF, DG, DLTR, MYL

The discount dollar stores quarterly results disappoint, while Tiffany beats profit forecasts.

Rev's Forum: Market Resets, Waiting for Janet Yellen

Rev's Forum: Market Resets, Waiting for Janet Yellen

The indexes' positive tone shifted in the last two days.

Mylan (MYL) Stock Gaining, Cuts EpiPen Costs Following Backlash

Mylan (MYL) Stock Gaining, Cuts EpiPen Costs Following Backlash

Mylan (MYL) said on Thursday that it would reduce the out-of-pocket cost of its EpiPens, which treat severe allergies.

Cramer: The Stock Market Is Helping the Consumer This Year

Cramer: The Stock Market Is Helping the Consumer This Year

It could well be the stock market, not the Fed, that is driving our retail and services.

Mylan Taking Immediate Action To Further Enhance Access To EpiPen® (Epinephrine Injection, USP) Auto-Injector

Mylan Taking Immediate Action To Further Enhance Access To EpiPen® (Epinephrine Injection, USP) Auto-Injector

Mylan doubling the eligibility for patient assistance, effectively eliminating out-of-pocket expense for uninsured and under-insured patients

Futures Lower Following Clinton EpiPen Tweet; Asia Opens Down Too

Futures Lower Following Clinton EpiPen Tweet; Asia Opens Down Too

Clinton hammers a whole sector by criticizing an increase in Epipens.

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Clinton goes after the drug companies again -- for starters.

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?

Ugly Underlying Action Should Stay Hidden

Market momentum cools, big time.

Closing Bell: Clinton Calls Out Mylan on Price Hikes; U.S. Stock Losses Grow

Closing Bell: Clinton Calls Out Mylan on Price Hikes; U.S. Stock Losses Grow

U.S. stock losses grew heavier Wednesday as the afternoon wore-on with a selloff in crude oil and health care stocks leading Wall Street into the red.

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.

Crude Oil, Health Care Team Up to Pull Wall Street Lower

Crude Oil, Health Care Team Up to Pull Wall Street Lower

A selloff in crude oil and health care stocks led Wall Street into the red on Wednesday.

Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again

Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again

The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.

More Squawk from Jim Cramer: Mylan (MYL) EpiPens 'Should Not Be Just for Rich People'

More Squawk from Jim Cramer: Mylan (MYL) EpiPens 'Should Not Be Just for Rich People'

Mylan (MYL) stock has slumped this week as the pharmaceutical company faces public criticism over the high price of its EpiPens.

BTIG's Chiang Explains on CNBC Why He's Sticking With Mylan (MYL)

BTIG's Chiang Explains on CNBC Why He's Sticking With Mylan (MYL)

BTIG managing director Tim Chiang joined CNBC's 'Power Lunch' Tuesday afternoon to explain the 'buy' rating he has on Mylan (MYL) shares.

Mylan (MYL) Stock Slides, Citigroup: EpiPen Scrutiny Could Drive Multiples Down

Mylan (MYL) Stock Slides, Citigroup: EpiPen Scrutiny Could Drive Multiples Down

Citigroup analysts say recent public scrutiny over Mylan's (MYL) EpiPen won't affect its earnings, but could 'weigh on the stock's multiple' in the near term.